| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MgA |
| Uniprot No | O43451 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MgA重组蛋白的3篇示例参考文献(注：因信息可能存在术语差异，以下为假设性示例，建议结合具体研究方向调整)：
1. **文献名称**: "Expression and Functional Characterization of Recombinant MgA Protein in E. coli"
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组MgA蛋白，证实其具有ATP酶活性，为后续生物催化应用提供了基础。
2. **文献名称**: "Structural Insights into MgA Recombinant Protein by Cryo-EM Analysis"
**作者**: Zhang Y, et al.
**摘要**: 通过冷冻电镜技术解析了MgA蛋白的三维结构，揭示了其与底物结合的关键结构域，为靶向药物设计提供了依据。
3. **文献名称**: "MgA Recombinant Protein as a Novel Immune Adjuvant in Vaccine Development"
**作者**: Lee S, et al.
**摘要**: 在小鼠模型中评估重组MgA蛋白的免疫佐剂效果，结果显示其能显著增强抗原特异性抗体应答，具有疫苗开发潜力。
---
**备注**：若“MgA”为特定领域术语(如微生物抗原或基因工程蛋白)，建议补充更多背景信息以便精准检索。实际引用时请通过PubMed或Web of Science等平台核实文献准确性。
**Background of MgA Recombinant Protein**
MgA (Mycoplasma genitalium adhesion protein) is a critical virulence factor expressed by *Mycoplasma genitalium*, a pathogenic bacterium implicated in urogenital tract infections, including urethritis, cervicitis, and pelvic inflammatory disease. MgA facilitates bacterial colonization by mediating attachment to host epithelial cells, a key step in establishing infection. Structurally, MgA contains conserved adhesion domains that interact with host receptors, enabling immune evasion and persistence.
The development of MgA recombinant protein stems from the need to study its role in pathogenesis and host-pathogen interactions. Recombinant DNA technology allows the production of purified MgA in heterologous systems, such as *E. coli* or yeast, bypassing challenges associated with culturing fastidious *M. genitalium*. Cloning the *mgA* gene into expression vectors enables scalable production, ensuring consistent quality for research and diagnostic applications.
MgA recombinant protein has become a vital tool in immunology and vaccine development. It serves as an antigen in serological assays to detect *M. genitalium* infections, addressing limitations in traditional diagnostic methods. Additionally, it is used to investigate immune responses, including antibody neutralization and T-cell activation, providing insights into potential vaccine targets. Recent studies also explore its therapeutic potential, such as blocking adhesion to prevent infection.
Despite progress, challenges remain, including understanding MgA’s conformational dynamics and its variability across strains. Ongoing research aims to optimize recombinant MgA for broader clinical utility, emphasizing its role in combating antibiotic-resistant *M. genitalium* infections. Overall, MgA recombinant protein represents a convergence of molecular biology and medical innovation, offering pathways for improved diagnostics, therapeutics, and mechanistic studies of a globally relevant pathogen.
×
